Willem K. Smits

Willem K. Smits

Auto-generated profile, based on publicly available information

Willem K. Smits

Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
KCKirsten Canté-Barrett
Kirsten Canté-Barrett
MMMariska T. Meijer
Mariska T. Meijer
VCValentina Cordo’
Valentina Cordo’
RHRico Hagelaar
Rico Hagelaar
WYWentao Yang
Wentao Yang
JMJules Meijerink
Jules Meijerink
Rearrangements that drive ectopic MEF2C expression have recurrently been found in patients with human early thymocyte progenitor acute lymphoblastic leukemia (ETP-ALL). Here, we show high levels of MEF2C expression in patients with ETP-ALL. Using both in vivo and in vitro models of ETP-ALL, we demonstrate that elevated MEF2C expression blocks NOTCH-induced T cell differentiation while promoting a B-lineage program. MEF2C activates a B cell transcriptional program in addition to RUNX1, GATA3, and LMO2; upregulates the IL-7R; and boosts cell survival by upregulation of BCL2. MEF2C and the Notch pathway, therefore, demarcate opposite regulators of B- or T-lineage choices, respectively. Enforced MEF2C expression in mouse or human progenitor cells effectively blocks early T cell differentiation and promotes the development of biphenotypic lymphoid tumors that coexpress CD3 and CD19, resembling human mixed phenotype acute leukemia. Salt-inducible kinase (SIK) inhibitors impair MEF2C activity and alleviate the T cell developmental block. Importantly, this sensitizes cells to prednisolone treatment. Therefore, SIK-inhibiting compounds such as dasatinib are potentially valuable additions to standard chemotherapy for human ETP-ALL.

14 April 2023 in Cell Reports
Verified
Journal Article
Open access
WSWillem K. Smits
Willem K. Smits
CVCarlo Vermeulen
Carlo Vermeulen
RHRico Hagelaar
Rico Hagelaar
SKShunsuke Kimura
Shunsuke Kimura
EVEric M. Vroegindeweij
Eric M. Vroegindeweij
JMJules Meijerink
Jules Meijerink
Monoallelic inactivation of CCCTC-binding factor (CTCF) in human cancer drives altered methylated genomic states, altered CTCF occupancy at promoter and enhancer regions, and deregulated global gene expression. In patients with T cell acute lymphoblastic leukemia (T-ALL), we find that acquired monoallelic CTCF-inactivating events drive subtle and local genomic effects in nearly half of t(5; 14) (q35; q32.2) rearranged patients, especially when CTCF-binding sites are preserved in between the BCL11B enhancer and the TLX3 oncogene. These solitary intervening sites insulate TLX3 from the enhancer by inducing competitive looping to multiple binding sites near the TLX3 promoter. Reduced CTCF levels or deletion of the intervening CTCF site abrogates enhancer insulation by weakening competitive looping while favoring TLX3 promoter to BCL11B enhancer looping, which elevates oncogene expression levels and leukemia burden.